Aerovate Therapeutics Inc
NASDAQ:AVTE

Watchlist Manager
Aerovate Therapeutics Inc Logo
Aerovate Therapeutics Inc
NASDAQ:AVTE
Watchlist
Price: 2.695 USD 0.56% Market Closed
Market Cap: 77.8m USD
Have any thoughts about
Aerovate Therapeutics Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

0.1
Current
-5.2
Median
4.2
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
0.1
=
Enterprise Value
-10.9m USD
/
EBITDA
-90m USD
All Countries
Close
EBITDA Growth
US
Aerovate Therapeutics Inc
NASDAQ:AVTE
Average EV/EBITDA: 14.8
0.1
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 224.1 N/A
US
Abbvie Inc
NYSE:ABBV
15.6
29%
US
Amgen Inc
NASDAQ:AMGN
16.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.8
43%
US
Gilead Sciences Inc
NASDAQ:GILD
10
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -515.4 N/A
AU
CSL Ltd
ASX:CSL
20.6
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.9 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.1 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A

See Also

Discover More